Our study further confirmed the view of an immunomodulatory role of IL-10 in the SARS-CoV-2 specific inflammatory response and highlights the therapeutic potential of the administration of rhu IL-10 to treat ARDS in COVID-19 patients, as already investigated for solid tumors and various autoimmune and inflammatory diseases (45). Here, IL10 is linked to COVID-19.